Status:
UNKNOWN
The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
Lead Sponsor:
Roshni Dasgupta
Conditions:
Metastatic Disease
Primary Tumor
Eligibility:
All Genders
1-45 years
Brief Summary
Use of indocyanine green will augment the accuracy of identification and resection of both primary solid malignancies as well as their pulmonary metastases, where applicable We will conduct a prospect...
Detailed Description
Patients diagnosed with solid malignancies or metastatic lesions who require clinically indicated resection will be identified by their Oncologist. The oncologist will inform the subject/family about ...
Eligibility Criteria
Inclusion
- All patients with newly diagnosed solid, primary malignancies or their related metastatic lesions.
- Diagnosis of primary or metastatic malignancy will be made by combination of:
- Clinical evaluation and physical exam
- Radiologic study including ultrasound, CT scan, and/or MRI
- Pathologic diagnosis after biopsy
Exclusion
- Those patients and parents/guardians unwilling to provide consent/assent.
- Pregnant and/or women who are breast feeding.
- Patients with Iodine allergies
Key Trial Info
Start Date :
June 5 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04492735
Start Date
June 5 2020
End Date
June 1 2025
Last Update
July 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio, United States, 45229